These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 1988613)

  • 1. Sensitivity of technetium-99m-d,1-HMPAO to radiolysis in aqueous solutions.
    Tubergen K; Corlija M; Volkert WA; Holmes RA
    J Nucl Med; 1991 Jan; 32(1):111-5. PubMed ID: 1988613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the stability of (99m)Tc-ECD and stabilized (99m)Tc-HMPAO stored in syringes.
    Koslowsky IL; Brake SE; Bitner SJ
    J Nucl Med Technol; 2001 Dec; 29(4):197-200. PubMed ID: 11756532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New synthesis route of active substance d,l-HMPAO for preparation Technetium Tc99m Exametazime.
    Pijarowska-Kruszyna J; Karczmarczyk U; Jaroń AW; Laszuk E; Radzik M; Garnuszek P; Mikołajczak R
    Nucl Med Rev Cent East Eur; 2017; 20(2):88-94. PubMed ID: 28555448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stability of stabilized 99mTc-D,L-HMPAO stored in vials and syringes.
    Del Carmen Plancha-Mansanet M; Caballero-Calabuig E; Félix-Fontestad J; Reyes-Ojeda MD; Sopena-Novales P; Abreu-Sánchez P; Del Carmen Cano-Terol M; Sopena-Monforte R
    J Nucl Med Technol; 2008 Dec; 36(4):213-6. PubMed ID: 19008289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiochemical purity of technetium-99m-HMPAO depends on specific activity.
    Piera C; Martínez A; Ramírez I
    J Nucl Med; 1995 Apr; 36(4):706. PubMed ID: 7699470
    [No Abstract]   [Full Text] [Related]  

  • 6. Influence of radiolytic-produced hydrogen peroxide on the stability of commercial kit (99m) technetium-exametazime preparation.
    Martinez T; Miñana E; Martín-Falquina TC; Fuente T
    J Labelled Comp Radiopharm; 2014 Jan; 57(1):49-52. PubMed ID: 24448745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stabilisation of high-activity 99mTc-d,l-HMPAO preparations with cobalt chloride and their biological behaviour.
    Mang'era KO; Vanbilloen HP; Schiepers CW; Verbruggen AM
    Eur J Nucl Med; 1995 Oct; 22(10):1163-72. PubMed ID: 8542901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of pertechnetate source and age on the radiochemical purity of technetium Tc 99m exametazime.
    Ponto JA
    Am J Hosp Pharm; 1990 Nov; 47(11):2511-3. PubMed ID: 2177584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of source and age of sodium pertechnetate Tc 99m on radiochemical purity of technetium Tc 99m exametazime.
    Millar AM
    Am J Hosp Pharm; 1993 Jan; 50(1):103-6. PubMed ID: 8381258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetic analysis of technetium-99m d,1-HM-PAO decomposition in aqueous media.
    Hung JC; Corlija M; Volkert WA; Holmes RA
    J Nucl Med; 1988 Sep; 29(9):1568-76. PubMed ID: 3411374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of technetium-99m-HMPAO and xenon-133 measurements of regional cerebral blood flow by SPECT.
    Payne JK; Trivedi MH; Devous MD
    J Nucl Med; 1996 Oct; 37(10):1735-40. PubMed ID: 8862321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship of decreased chemotaxis of technetium-99m-HMPAO-labeled lymphocytes to apoptosis.
    Van de Wiele C; Philippé J; Van Haelst JP; Van Damme J; Thierens H; Leroux-Roels GE; Dierckx RA
    J Nucl Med; 1997 Sep; 38(9):1417-21. PubMed ID: 9293800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative study of 99Tcm-HMPAO and 99Tcm-ECD as a leukocyte labelling agent.
    Kao CH; Huang WT; Wang YL; Lin KS; Lo JM; Wang SJ
    Nucl Med Commun; 1994 Apr; 15(4):294-7. PubMed ID: 8072744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of metabolic alterations on the accumulation of technetium-99m-labeled d,l-HMPAO in slices of rat cerebral cortex.
    Ahn CS; Tow DE; Yu CC; Greene RW
    J Cereb Blood Flow Metab; 1994 Mar; 14(2):324-31. PubMed ID: 8113327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A method for stabilising technetium-99m exametazime prepared from a commercial kit.
    Weisner PS; Bower GR; Dollimore LA; Forster AM; Higley B; Storey AE
    Eur J Nucl Med; 1993 Aug; 20(8):661-6. PubMed ID: 8404951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Routine application of fractionated HMPAO stored at -70 degrees C for WBC scintigraphy.
    Morrissey GJ; Powe JE
    J Nucl Med; 1993 Jan; 34(1):151-5. PubMed ID: 8418259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intracellular localization of (99m)Tc-d,l-HMPAO in rat blood.
    Al-Saeedi FJ; Gopinath S
    Med Princ Pract; 2009; 18(6):466-9. PubMed ID: 19797923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 99mTc-D,L-hexamethylene-propyleneamine oxime (99mTc-HMPAO): basic kinetic studies of a tracer of cerebral blood flow.
    Andersen AR
    Cerebrovasc Brain Metab Rev; 1989; 1(4):288-318. PubMed ID: 2701656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 99mTc-HMPAO as a tracer of cerebral blood flow in newborn infants.
    Børch K; Greisen G
    J Cereb Blood Flow Metab; 1997 Apr; 17(4):448-54. PubMed ID: 9143227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphocyte labeling with technetium-99m-HMPAO: a radiotoxicity study using the micronucleus assay.
    Thierens HM; Vral AM; Van Haelst JP; Van de Wiele C; Schelstraete KH; de Ridder LI
    J Nucl Med; 1992 Jun; 33(6):1167-74. PubMed ID: 1597733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.